Publication

Article

Pharmacy Practice in Focus: Oncology

August 2020
Volume2
Issue 4

CE: Advanced Melanoma: A Pharmacist’s Guide to Treatment and Patient Management for New and Emerging Drug Therapies

This activity is supported by an educational grant from Merck Sharp & Dohme Corp..

This activity is supported by an educational grant from Merck Sharp & Dohme Corp..

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

  • Explain how genetic mutations and biomarkers influence therapy selection for the treatment of cutaneous melanoma
  • Identify appropriate adjuvant therapy for the treatment of a patient with cutaneous melanoma based on patient- and disease-specific factors
  • Examine guideline recommendations to appropriately place targeted therapies in a patient’s treatment algorithm for advanced melanoma
  • Identify strategies that pharmacists can employ to overcome challenges commonly seen in the management of patients with advanced melanoma

FACULTY

Heather Armbruster, PharmD, BCOP

Specialty Practice Pharmacist, Melanoma

The Ohio State University , James Comprehensive Cancer Center, Columbus, Ohio

TARGET AUDIENCE: Oncology, health-system, and specialty pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: August 14, 2020

EXPIRATION DATE: February 14, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.

Related Videos
3d rendering of Bispecific antibodies or BsAbs have two distinct binding domains that can bind to two antigens or two epitopes of the same antigen simultaneously